Tranzyme Pharma's DIGEST Trial Stopped for Futility After Interim Analysis of the Phase 2b Results

Tranzyme Pharma's DIGEST Trial Stopped for Futility After Interim Analysis of
the Phase 2b Results

RESEARCH TRIANGLE PARK, N.C., Dec. 17, 2012 (GLOBE NEWSWIRE) -- Tranzyme
Pharma (Nasdaq:TZYM) today announced it is discontinuing and immediately
ending patient enrollment inDIGEST, a Phase 2b trial in diabetic patients
receiving TZP-102 for the management of symptoms of gastroparesis, due to
insufficient efficacy. The decision followed a planned interim futility
analysis, which examined patients' responsiveness to thrice daily oral dosing
of 10mg of TZP-102 or placebo at the end of weeks 4 and 8 of a 12 week trial.
The results are consistent with the findings of a prior Phase 2b trial in that
there was a very large placebo effect and no treatment effect.

About Tranzyme Pharma

Tranzyme Pharma is a biopharmaceutical company focused on discovering,
developing and commercializing novel, mechanism-based therapeutics for the
treatment of upper gastrointestinal (GI) motility disorders. While
approximately 40 percent of people in the U.S. are affected by these
persistent and recurring conditions which disrupt the normal movement of food
throughout the GI tract, there are a limited number of safe and effective
treatment options. By leveraging its proprietary drug discovery technology,
MATCH™, Tranzyme is committed to pursuing first-in-class medicines to address
areas of significant unmet medical needs.

Further information about Tranzyme Pharma can be found on the Company's web
site at www.tranzyme.com.

CONTACT: Corporate Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109
         ssharpe@tranzyme.com
        
         Investor Inquiries:
         David Carey
         Lazar Partners, Ltd.
         (212) 867-1768
         dcarey@lazarpartners.com
 
Press spacebar to pause and continue. Press esc to stop.